Stock Events

Stock Events

Iterum Therapeutics

$0.02

90

-$0.03-66.67% Wednesday 18:40

Statistics

Day High

0.02

Day Low

0.02

52W High

1.42

52W Low

0.01

Volume

-

Avg. Volume

-

Mkt Cap

0

P/E Ratio

-

Dividend Yield

-

Dividend

-

Upcoming

Earnings

26MayExpected

Next

-0.1

0.23

0.57

0.9

Expected EPS

-0.1

Actual EPS

N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ITRMF. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Pfizer is a major pharmaceutical company that competes with Iterum Therapeutics in the development and marketing of antibiotics and treatments for infections, a key area for Iterum.

Merck & Co., Inc. is involved in the discovery, development, manufacturing, and marketing of pharmaceuticals, including anti-infectives, directly competing with Iterum's product offerings.

GlaxoSmithKline plc focuses on creating vaccines and antibiotics, competing with Iterum Therapeutics in the antibiotics market.

AbbVie Inc. operates in the pharmaceuticals sector, including the development of anti-infective therapies, making it a competitor to Iterum Therapeutics.

Johnson & Johnson

Johnson & Johnson, through its pharmaceutical segment, develops and sells products in various therapeutic areas, including infectious diseases, competing with Iterum.

Novartis AG is a global healthcare company that has a strong presence in the development of drugs for infectious diseases, competing with Iterum Therapeutics.

AstraZeneca PLC is involved in the discovery and development of antibiotics, directly competing with Iterum Therapeutics in the anti-infective space.

Sanofi is a global life sciences company that focuses on healthcare solutions, including antibiotics, making it a competitor to Iterum Therapeutics.

Teva- Pharmaceutical Industries

Teva Pharmaceutical Industries Limited operates in generic and specialty medicines, including the development of anti-infective drugs, competing with Iterum.

Seres Therapeutics

Seres Therapeutics, Inc. focuses on microbiome therapeutics for infections and other conditions, representing a novel competition to Iterum Therapeutics in the infectious disease sector.

About

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.

Show more...

CEO

Mr. Corey N. Fishman

Employees

9

Country

Ireland

ISIN

IE000TTOOBX0

Listings

0 Comments

Share your thoughts

FAQ

What is Iterum Therapeutics stock price today?▼

The current price of ITRMF is $0.02 USD — it has decreased by -66.67% in the past 24 hours. Watch Iterum Therapeutics stock price performance more closely on the chart.

What is Iterum Therapeutics stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on exchange Iterum Therapeutics stocks are traded under the ticker ITRMF.

How many employees does Iterum Therapeutics have?▼

As of May 26, 2026, the company has 9 employees.

In which sector is Iterum Therapeutics located?▼

Iterum Therapeutics operates in the Health & Wellness sector.

When did Iterum Therapeutics complete a stock split?▼

Iterum Therapeutics has not had any recent stock splits.

Where is Iterum Therapeutics headquartered?▼

Iterum Therapeutics is headquartered in Dublin, Ireland.